30. May 2026
The AMNOG-Monitor has a fresh look
The AMNOG-Monitor now has a fresh look. After rebuilding the platform from the ground up last year to handle additional data sources such as EU-HTA and arbitration rulings, we've also …
G-BA Resolutions.
Clearly analysed.
The AMNOG-Monitor provides all relevant information on early benefit assessment and price negotiations, updated daily. A solid foundation for Market Access, HTA, Medical, Business Development, and Pricing.
Current resolutions
News
All articles
Read more →
04. May 2026
The new European health technology assessment (EU-HTA) has reached an important milestone
The new European health technology assessment (EU-HTA) has reached an important milestone: the first joint assessment – led by Ireland's National Centre for Pharmacoeconomics (NCPE) as assessor and IQWiG as …
16. April 2026
G-BA finds no added benefit for the second early-Alzheimer's drug either
The Federal Joint Committee (G-BA) has found no added benefit over the current standard of care for the second new drug to treat early-stage Alzheimer's disease either. The decision is …
Features at a glance
Individual decision at a glance
Key data from all AMNOG decisions, summarized in a compact and structured format.
Interactive analysis
Analyze your own research questions by filtering across more than 120 parameters.
Smart search
Fast, quality-assured analysis of original documents such as dossiers, G-BA decisions, arbitration rulings, and clinical trials.
Price trends and annual therapy cost tracking
Price trends for all AMNOG drugs at PZN level and for annual therapy costs. Tracking of all appropriate comparator therapies (ZVT) and their weighting (on request).
EU-HTA
EU dossiers and JCAs will be integrated into the AMNOG-Monitor as soon as the first ones become available.
Export and bookmarks
Export analysis results to Excel, PowerPoint, or Word with links back to the AMNOG-Monitor. Save standard queries for price changes or new indications using bookmarks.